Key Highlights

  • HYFT shares have gone quiet, even as the company reports record Revenue and improved margins following its rebrand.
  • MindWalk reported record quarterly revenue of $7.6 million, up 45% year over year, with gross margins around 53%.
  • The company strengthened its Balance Sheet with roughly $16.1 million in net proceeds from divesting its Netherlands operations.
  • MindWalk is building its Business around AI-driven drug discovery through its LensAI platform and HYFT data framework.

MindWalk Holdings Corp. (NASDAQ:HYFT) is a company in the midst of reinvention, and understanding it requires knowing its recent history: it is the former ImmunoPrecise Antibodies, rebranded in September 2025 as it repositioned from a wet-lab antibody-services provider into an AI-focused Biologics platform company. After a quiet stretch, the question is whether that transformation is setting up a surprise move.

Under the MindWalk name, the company is building its business around AI-driven drug discovery, using proprietary technology it markets as its LensAI platform and HYFT data framework, the latter reflected in its ticker. The strategy is to help pharmaceutical partners accelerate discovery and de-risk development, shifting the company toward a higher-value, technology-driven model and away from traditional laboratory services.

Latest Developments

MindWalk reported record quarterly revenue of $7.6 million, up 45% year over year, with gross margins around 53% and reduced operating losses, while strengthening its balance sheet with roughly $16.1 million in net proceeds from divesting its Netherlands operations.

The company has pointed to applications of its AI platform including antidrug-antibody risk prediction and advancing a dengue Vaccine program through preclinical work. The combination of a rebrand, revenue growth, improved margins and a cash infusion from the divestiture reflects a company actively reshaping itself around its AI ambitions.

Financial and Business Position

MindWalk's transition carries both promise and uncertainty. Growing revenue with improving margins and a strengthened balance sheet suggests the underlying business is gaining traction, and the divestiture proceeds provide flexibility to invest in the AI platform.

However, positioning a former services company as an AI-driven biologics platform is an ambitious repositioning, and the ultimate value depends on whether its technology delivers differentiated results for pharmaceutical partners and translates into durable, scalable revenue.

Stock-Market Context

HYFT's quiet stretch sits against real optimism about the AI-platform strategy and the recent revenue momentum. The surprise-move case rests on the LensAI and HYFT technologies gaining validation and partners, driving sustained growth; the cautionary case is that AI-in-drug-discovery is a crowded, still-maturing field.

What Investors Should Watch

Investors may focus on continued revenue growth and Margin trends, evidence that the LensAI platform and HYFT technology are winning pharmaceutical partnerships and producing tangible results, progress on programs such as the dengue vaccine work, and how the company deploys its divestiture proceeds.

MindWalk's transformation is emblematic of a broader wave of companies repositioning themselves around artificial intelligence, and the key question for investors is always whether the shift is substantive or largely a matter of branding. Growing revenue, healthy gross margins and a strengthened balance sheet suggest the underlying business has genuine momentum.